HomeCompareKMPH vs BTI

KMPH vs BTI: Dividend Comparison 2026

KMPH yields 34.42% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMPH wins by $132.6K in total portfolio value
10 years
KMPH
KMPH
● Live price
34.42%
Share price
$5.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$170.3K
Annual income
$25,361.80
Full KMPH calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — KMPH vs BTI

📍 KMPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKMPHBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KMPH + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KMPH pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KMPH
Annual income on $10K today (after 15% tax)
$2,925.99/yr
After 10yr DRIP, annual income (after tax)
$21,557.53/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, KMPH beats the other by $19,188.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KMPH + BTI for your $10,000?

KMPH: 50%BTI: 50%
100% BTI50/50100% KMPH
Portfolio after 10yr
$104.0K
Annual income
$14,074.22/yr
Blended yield
13.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

KMPH
Analyst Ratings
2
Buy
Consensus: Buy
Price Target
$10.00
+72.1% upside vs current
Range: $10.00 — $10.00
Altman Z
-0.8
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KMPH buys
0
BTI buys
0
No recent congressional trades found for KMPH or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKMPHBTI
Forward yield34.42%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$170.3K$37.7K
Annual income after 10y$25,361.80$2,786.64
Total dividends collected$122.2K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$10.00$40.00

Year-by-year: KMPH vs BTI ($10,000, DRIP)

YearKMPH PortfolioKMPH Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$14,142$3,442.34$11,299$598.92+$2.8KKMPH
2$19,682$4,549.79$12,794$703.91+$6.9KKMPH
3$26,978$5,917.76$14,518$829.07+$12.5KKMPH
4$36,447$7,580.64$16,513$978.64+$19.9KKMPH
5$48,569$9,571.43$18,827$1,157.84+$29.7KKMPH
6$63,890$11,920.58$21,518$1,373.12+$42.4KKMPH
7$83,017$14,654.90$24,657$1,632.46+$58.4KKMPH
8$106,625$17,796.49$28,329$1,945.74+$78.3KKMPH
9$135,450$21,361.97$32,637$2,325.33+$102.8KKMPH
10$170,294$25,361.80$37,708$2,786.64+$132.6KKMPH

KMPH vs BTI: Complete Analysis 2026

KMPHStock

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Full KMPH Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this KMPH vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KMPH vs SCHDKMPH vs JEPIKMPH vs OKMPH vs KOKMPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.